secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K/A
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001575872-23-000150
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital Acquisition Corp. enters merger agreement with Longevity Biomedical
--------------------------------------------------------------------------------

- Denali entered into a merger agreement with Longevity Biomedical, Inc. on Jan 25, 2023, with a total enterprise value of $128 million.
- Under the merger, Denali SPAC Holdco will become New PubCo, renamed Longevity Biomedical, expected to list on NASDAQ under ticker LBIO.
- The transaction requires approval by Denali shareholders and other conditions, including net tangible assets of at least $5,000,001 after redemptions.
- Sponsor and Investor FutureTech Capital agreed to purchase 625,000 Class B units for $5 million, with $2 million already paid.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000157587223000150/0001575872-23-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000157587223000150/deca-20230125.htm
  HTML page:      https://secwatch.observer/filing/0001575872-23-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer